{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T15:00:54Z","timestamp":1740150054594,"version":"3.37.3"},"reference-count":30,"publisher":"Bentham Science Publishers Ltd.","issue":"11","funder":[{"DOI":"10.13039\/501100003069","name":"Instituto Polit\u00e9cnico Nacional","doi-asserted-by":"publisher","award":["Proyectos Insignia IPN-2015"],"award-info":[{"award-number":["Proyectos Insignia IPN-2015"]}],"id":[{"id":"10.13039\/501100003069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"CONACYT","doi-asserted-by":"publisher","award":["CB-254600","APN-782","SEPCONACYT-ANUIES-ECOS Francia: 296636"],"award-info":[{"award-number":["CB-254600","APN-782","SEPCONACYT-ANUIES-ECOS Francia: 296636"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["ACAMC"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n<jats:title>Background and Objective:<\/jats:title>\n<jats:p>Histone Deacetylases (HDACs) are important therapeutic targets for\nmany types of human cancers. A derivative of valproic acid, N-(2-hydroxyphenyl)-2-propylpentanamide (HOAAVPA),\nhas antiproliferative properties on some cancer cell lines and inhibits the HDAC1 isoform.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Materials and Methods:<\/jats:title>\n<jats:p> In this work, HO-AAVPA was tested as an antiproliferative agent in U87-MG (human\nglioblastoma) and U-2 OS cells (human osteosarcoma), which are types of cancer that are difficult to treat, and its\nantiangiogenic properties were explored.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>HO-AAVPA had antiproliferative effects at 48h with an IC<jats:sub>50<\/jats:sub>=0.655mM in U87-MG cells and an\nIC<jats:sub>50<\/jats:sub>=0.453mM in U-2 OS cells. Additionally, in the colony formation assay, HO-AAVPA decreased the number\nof colonies by approximately 99% in both cell lines and induced apoptosis by 31.3% in the U-2 OS cell line and\nby 78.2% in the U87-MG cell line. Additionally, HO-AAVPA reduced the number of vessels in Chorioallantoic\nMembranes (CAMs) by approximately 67.74% and IL-6 levels in both cell lines suggesting that the biochemical\nmechanism on cancer cell of HO-AAVPA is different compared to VPA.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>HO-AAVPA has antiproliferative effects on glioblastoma and osteosarcoma and antiangiogenic properties.\n<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871520620666200728125356","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T06:25:43Z","timestamp":1596003943000},"page":"1451-1459","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Apoptotic Effects of N-(2-Hydroxyphenyl)-2-Propylpentanamide on U87-MG and U-2 OS Cells and Antiangiogenic Properties"],"prefix":"10.2174","volume":"21","author":[{"given":"Paola","family":"Castillo-Ju\u00e1rez","sequence":"first","affiliation":[{"name":"Department of Microbiology, Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Carpio y Plan de Ayala S\/N, Casco de Santo Tomas, Mexico, CDMX. 11340,Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebasti\u00e1n C.","family":"Sanchez","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Carpio y Plan de Ayala S\/N, Casco de Santo Tomas, Mexico, CDMX. 11340,Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alma D.","family":"Ch\u00e1vez-Blanco","sequence":"additional","affiliation":[{"name":"Subdireccion de Investigacion Basica, Intituto Nacional de Cancerologia, Ciudad de Mexico,Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Humberto L.","family":"Mendoza-Figueroa","sequence":"additional","affiliation":[{"name":"Laboratorio de Diseno y Desarrollo de Nuevos Farmacos e Innovacion Biotecnologica, Escuela Superior de Medicina, Instituto Politecnico Nacional, Plan de San Luis y D\u00edaz Miron, Ciudad de Mexico 11340,Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Correa-Basurto","sequence":"additional","affiliation":[{"name":"Laboratorio de Diseno y Desarrollo de Nuevos Farmacos e Innovacion Biotecnologica, Escuela Superior de Medicina, Instituto Politecnico Nacional, Plan de San Luis y D\u00edaz Miron, Ciudad de Mexico 11340,Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"148","DOI":"10.18388\/pb.2018_125","volume":"64","author":"Maleszewska M.","year":"2018","unstructured":"Maleszewska M.; Wojtas B.; Kami\u0144ska B.; Deregulation of epigenetic mechanisms in cancer. Postepy Biochem 2018,64(2),148-156","journal-title":"Postepy Biochem"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/med.20024","volume":"25","author":"Mai A.","year":"2005","unstructured":"Mai A.; Massa S.; Rotili D.; Cerbara I.; Valente S.; Pezzi R.; Simeoni S.; Ragno R.; Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev 2005,25(3),261-309","journal-title":"Med Res Rev"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/3-7643-7414-4_7","volume":"63","author":"Palmieri C.","year":"2005","unstructured":"Palmieri C.; Coombes R.C.; Vigushin D.M.; Targeted histone deacetylase inhibition for cancer prevention and therapy. Prog Drug Res 2005,63,147-181","journal-title":"Prog Drug Res"},{"key":"ref=4","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a018713","volume":"6","author":"Seto E.","year":"2014","unstructured":"Seto E.; Yoshida M.; Erasers of histone acetylation: The histone deacetylase enzymes. Cold Spring Harb Perspect Biol 2014,6(4)","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1096\/fj.14-250654","volume":"28","author":"Yang H.","year":"2014","unstructured":"Yang H.; Salz T.; Zajac-Kaye M.; Liao D.; Huang S.; Qiu Y.; Overexpression of histone deacetylases in cancer cells is controlled by interplay of transcription factors and epigenetic modulators. FASEB J 2014,28(10),4265-4279","journal-title":"FASEB J"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2174\/138920007780655397","volume":"8","author":"Santini V.","year":"2007","unstructured":"Santini V.; Gozzini A.; Ferrari G.; Histone deacetylase inhibitors: Molecular and biological activity as a premise to clinical application. Curr Drug Metab 2007,8(4),383-393","journal-title":"Curr Drug Metab"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.canlet.2008.11.012","volume":"280","author":"Ellis L.","year":"2009","unstructured":"Ellis L.; Hammers H.; Pili R.; Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett 2009,280(2),145-153","journal-title":"Cancer Lett"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00280-010-1324-y","volume":"66","author":"Noureen N.","year":"2010","unstructured":"Noureen N.; Rashid H.; Kalsoom S.; Identification of type-specific anticancer histone deacetylase inhibitors: Road to success. Cancer Chemother Pharmacol 2010,66(4),625-633","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1615\/CritRevOncog.2015012997","volume":"20","author":"Chen H.P.","year":"2015","unstructured":"Chen H.P.; Zhao Y.T.; Zhao T.C.; Histone deacetylases and mechanisms of regulation of gene expression. Crit Rev Oncog 2015,20(1-2),35-47","journal-title":"Crit Rev Oncog"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1038\/s41467-018-05982-z","volume":"9","author":"Liu T.","year":"2018","unstructured":"Liu T.; Ma W.; Xu H.; Huang M.; Zhang D.; He Z.; Zhang L.; Brem S.; O\u2019Rourke D.M.; Gong Y.; Mou Y.; Zhang Z.; Fan Y.; PDGF-mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma. Nat Commun 2018,9(1),3439","journal-title":"Nat Commun"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1007\/s00264-012-1663-x","volume":"36","author":"Rastogi S.","year":"2012","unstructured":"Rastogi S.; Kumar R.; Sankineani S.R.; Marimuthu K.; Rijal L.; Prakash S.; Jalan D.; Khan S.A.; Sharma M.C.; Role of vascular endothelial growth factor as a tumour marker in osteosarcoma: A prospective study. Int Orthop 2012,36(11),2315-2321","journal-title":"Int Orthop"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/BF02478931","volume":"19","author":"Sawa H.","year":"2002","unstructured":"Sawa H.; Murakami H.; Ohshima Y.; Murakami M.; Yamazaki I.; Tamura Y.; Mima T.; Satone A.; Ide W.; Hashimoto I.; Kamada H.; Histone deacetylase inhibitors such as sodium butyrate and trichostatin A inhibit Vascular Endothelial Growth Factor (VEGF) secretion from human glioblastoma cells. Brain Tumor Pathol 2002,19(2),77-81","journal-title":"Brain Tumor Pathol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1093\/emboj\/cdg315","volume":"22","author":"Kr&#xE4;mer O.H.","year":"2003","unstructured":"Kr&#xE4;mer O.H.; Zhu P.; Ostendorff H.P.; Golebiewski M.; Tiefenbach J.; Peters M.A.; Brill B.; Groner B.; Bach I.; Heinzel T.; G&#xF6;ttlicher M.; The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J 2003,22(13),3411-3420","journal-title":"EMBO J"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1046\/j.1528-1157.2003.07202.x","volume":"44","author":"Gopaul S.","year":"2003","unstructured":"Gopaul S.; Farrell K.; Abbott F.; Effects of age and polytherapy, risk factors of Valproic Acid (VPA) hepatotoxicity, on the excretion of thiol conjugates of (E)-2,4-diene VPA in people with epilepsy taking VPA. Epilepsia 2003,44(3),322-328","journal-title":"Epilepsia"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"984","DOI":"10.2174\/1871520614666140127113218","volume":"14","author":"Luna-Palencia G.","year":"2014","unstructured":"Luna-Palencia G.; Martinez-Ramos F.; Vasquez-Moctezuma I.; Fragoso-Vazquez M.; Mendieta-Wejebe J.; Padilla-Mart&#xED;nez I.; Three amino acid derivatives of valproic acid: Design, synthesis, theoretical and experimental evaluation as anticancer agents. Anti-Cancer Agents Med Chem 2014,14,984-993","journal-title":"Anti-Cancer Agents Med Chem"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1080\/14756366.2016.1210138","volume":"31","author":"Prestegui-Martel B.","year":"2016","unstructured":"Prestegui-Martel B.; Berm&#xFA;dez-Lugo J.A.; Ch&#xE1;vez-Blanco A.; Due&#xF1;as-Gonz&#xE1;lez A.; Garc&#xED;a-S&#xE1;nchez J.R.; P&#xE9;rez-Gonz&#xE1;lez O.A.; Padilla-Mart&#xED;nez I.I.; Fragoso-V&#xE1;zquez M.J.; Mendieta-Wejebe J.E.; Correa-Basurto A.M.; M&#xE9;ndez-Luna D.; Trujillo-Ferrara J.; Correa-Basurto J.; N-(2-hydroxyphenyl)-2-propylpentanamide, a valproic acid aryl derivative designed in silico with improved antiproliferative activity in HeLa, rhabdomyosarcoma and breast cancer cells. J Enzyme Inhib Med Chem 2016,31(sup3),140-149","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jpba.2018.09.010","volume":"162","author":"Correa-Basurto A.M.","year":"2019","unstructured":"Correa-Basurto A.M.; Romero-Castro A.; Correa-Basurto J.; Hern&#xE1;ndez-Rodr&#xED;guez M.; Soriano-Urs&#xFA;a M.A.; Garc&#xED;a-Machorro J.; Tolentino-L&#xF3;pez L.E.; Rosales-Hern&#xE1;ndez M.C.; Mendieta-Wejebe J.E.; Pharmacokinetics and tissue distribution of N-(2-hydroxyphenyl)-2-propylpentanamide in Wistar Rats and its binding properties to human serum albumin. J Pharm Biomed Anal 2019,162,130-139","journal-title":"J Pharm Biomed Anal"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/BF00051376","volume":"7","author":"von Hoff D.D.","year":"1988","unstructured":"von Hoff D.D.; Human tumor cloning assays: applications in clinical oncology and new antineoplastic agent development. Cancer Metastasis Rev 1988,7(4),357-371","journal-title":"Cancer Metastasis Rev"},{"key":"ref=19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11030316","volume":"11","author":"Katayama Y.","year":"2019","unstructured":"Katayama Y.; Uchino J.; Chihara Y.; Tamiya N.; Kaneko Y.; Yamada T.; Takayama K.; Tumor neovascularization and developments in therapeutics. Cancers (Basel) 2019,11(3)","journal-title":"Cancers (Basel)"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1515\/rjim-2015-0027","volume":"53","author":"Costache M.I.","year":"2015","unstructured":"Costache M.I.; Ioana M.; Iordache S.; Ene D.; Costache C.A.; S\u0103ftoiu A.; VEGF expression in pancreatic cancer and other malignancies: A review of the literature. Rom J Intern Med 2015,53(3),199-208","journal-title":"Rom J Intern Med"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature01322","volume":"420","author":"Coussens L.M.","year":"2002","unstructured":"Coussens L.M.; Werb Z.; Coussens L.M.; Werb Z.; Inflammation and cancer. Nature 2002,420(6917),860-867","journal-title":"Nature"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"Hanahan D.","year":"2011","unstructured":"Hanahan D.; Weinberg R.A.; Hallmarks of cancer: The next generation. Cell 2011,144(5),646-674","journal-title":"Cell"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"7785","DOI":"10.7314\/APJCP.2014.15.18.7785","volume":"15","author":"Farooq M.","year":"2014","unstructured":"Farooq M.; El-Faham A.; Khattab S.N.; Elkayal A.M.; Ibrahim M.F.; Taha N.A.; Baabbad A.; Wadaan M.A.; Hamed E.A.; Biological screening of novel derivatives of valproic acid for anticancer and antiangiogenic properties. Asian Pac J Cancer Prev 2014,15(18),7785-7792","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s11060-007-9402-7","volume":"85","author":"Das C.M.","year":"2007","unstructured":"Das C.M.; Aguilera D.; Vasquez H.; Prasad P.; Zhang M.; Wolff J.E.; Gopalakrishnan V.; Valproic acid induces p21 and topoisomerase-II (&#x3B1;\/&#x3B2;) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. J Neurooncol 2007,85(2),159-170","journal-title":"J Neurooncol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"33368","DOI":"10.18632\/oncotarget.26077","volume":"9","author":"Contis-Montes de Oca A.","year":"2018","unstructured":"Contis-Montes de Oca A.; Rodarte-Valle E.; Rosales-Hern&#xE1;ndez M.C.; Abarca-Rojano E.; Rojas-Hern&#xE1;ndez S.; Fragoso-V&#xE1;zquez M.J.; Mendieta-Wejebe J.E.; Correa-Basurto A.M.; V&#xE1;zquez-Moctezuma I.; Correa-Basurto J.; N-(2\u2032-Hydroxyphenyl)-2-propylpentanamide (OH-VPA), a histone deacetylase inhibitor, induces the release of nuclear HMGB1 and modifies ROS levels in HeLa cells. Oncotarget 2018,9(70),33368-33381","journal-title":"Oncotarget"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1158\/0008-5472.CAN-15-1227","volume":"75","author":"Gopinathan G.","year":"2015","unstructured":"Gopinathan G.; Milagre C.; Pearce O.M.T.; Reynolds L.E.; Hodivala-Dilke K.; Leinster D.A.; Zhong H.; Hollingsworth R.E.; Thompson R.; Whiteford J.R.; Balkwill F.; Interleukin-6 stimulates defective angiogenesis. Cancer Res 2015,75(15),3098-3107","journal-title":"Cancer Res"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s10822-020-00304-2","volume":"34","author":"Sixto-L&#xF3;pez Y.","year":"2020","unstructured":"Sixto-L&#xF3;pez Y.; Bello M.; Correa-Basurto J.; Exploring the inhibitory activity of valproic acid against the HDAC family using an MMGBSA approach. J Comput Aided Mol Des 2020,34(8),857-878","journal-title":"J Comput Aided Mol Des"},{"key":"ref=28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20051110","volume":"20","author":"Gatla H.R.","year":"2019","unstructured":"Gatla H.R.; Muniraj N.; Thevkar P.; Yavvari S.; Sukhavasi S.; Makena M.R.; Regulation of chemokines and cytokines by histone deacetylases and an update on histone decetylase inhibitors in human diseases. Int J Mol Sci 2019,20(5)","journal-title":"Int J Mol Sci"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/imr.12614","volume":"281","author":"Mantovani A.","year":"2018","unstructured":"Mantovani A.; Barajon I.; Garlanda C.; IL-1 and IL-1 regulatory pathways in cancer progression and therapy. Immunol Rev Europe PMC Funders Group2018,281(1),57-61","journal-title":"Immunol Rev"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.smim.2014.01.008","volume":"26","author":"Fisher D.T.","year":"2014","unstructured":"Fisher D.T.; Appenheimer M.M.; Evans S.S.; The two faces of IL-6 in the tumor microenvironment. Semin Immunol 2014,26(1),38-47","journal-title":"Semin Immunol"}],"container-title":["Anti-Cancer Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871520620666200728125356","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/184220\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871520620666200728125356","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,5]],"date-time":"2022-06-05T15:47:00Z","timestamp":1654444020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/184220\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871520620666200728125356","relation":{},"ISSN":["1871-5206"],"issn-type":[{"type":"print","value":"1871-5206"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-02-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}